PIK3C3 and cancer: Recently, autophagy has emerged as an attractive target for cancer therapy and selective PIK3C3 inhibitors were also developed as a new approach to block autophagy, such as the pyrimidinone (SAR405) and the bisaminopyrimidine (VPS34-IN1, PIK-III) compounds [14,15].